156 related articles for article (PubMed ID: 11358453)
1. Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease.
Silverdale MA; McGuire S; McInnes A; Crossman AR; Brotchie JM
Exp Neurol; 2001 Jun; 169(2):400-6. PubMed ID: 11358453
[TBL] [Abstract][Full Text] [Related]
2. Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease.
Segovia G; Mora F; Crossman AR; Brotchie JM
Mov Disord; 2003 Feb; 18(2):138-49. PubMed ID: 12539206
[TBL] [Abstract][Full Text] [Related]
3. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease.
Lastres-Becker I; Hansen HH; Berrendero F; De Miguel R; Pérez-Rosado A; Manzanares J; Ramos JA; Fernández-Ruiz J
Synapse; 2002 Apr; 44(1):23-35. PubMed ID: 11842443
[TBL] [Abstract][Full Text] [Related]
4. Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain during late gestation and early postnatal period.
Berrendero F; Sepe N; Ramos JA; Di Marzo V; Fernández-Ruiz JJ
Synapse; 1999 Sep; 33(3):181-91. PubMed ID: 10420166
[TBL] [Abstract][Full Text] [Related]
5. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease.
Di Marzo V; Hill MP; Bisogno T; Crossman AR; Brotchie JM
FASEB J; 2000 Jul; 14(10):1432-8. PubMed ID: 10877836
[TBL] [Abstract][Full Text] [Related]
6. Distribution and modulation of histamine H(3) receptors in basal ganglia and frontal cortex of healthy controls and patients with Parkinson's disease.
Anichtchik OV; Peitsaro N; Rinne JO; Kalimo H; Panula P
Neurobiol Dis; 2001 Aug; 8(4):707-16. PubMed ID: 11493035
[TBL] [Abstract][Full Text] [Related]
7. Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism.
St-Hilaire M; Landry E; Lévesque D; Rouillard C
Neurobiol Dis; 2005 Nov; 20(2):450-60. PubMed ID: 15896973
[TBL] [Abstract][Full Text] [Related]
8. Receptor-activity modifying protein 1 expression is increased in the striatum following repeated L-DOPA administration in a 6-hydroxydopamine lesioned rat model of Parkinson's disease.
Lee J; Gomez-Ramirez J; Johnston TH; Visanji N; Brotchie JM
Synapse; 2008 Apr; 62(4):310-3. PubMed ID: 18241048
[TBL] [Abstract][Full Text] [Related]
9. A role for vanilloid receptor 1 (TRPV1) and endocannabinnoid signalling in the regulation of spontaneous and L-DOPA induced locomotion in normal and reserpine-treated rats.
Lee J; Di Marzo V; Brotchie JM
Neuropharmacology; 2006 Sep; 51(3):557-65. PubMed ID: 16806299
[TBL] [Abstract][Full Text] [Related]
10. Differential upregulation of the cannabinoid CB₂ receptor in neurotoxic and inflammation-driven rat models of Parkinson's disease.
Concannon RM; Okine BN; Finn DP; Dowd E
Exp Neurol; 2015 Jul; 269():133-41. PubMed ID: 25895887
[TBL] [Abstract][Full Text] [Related]
11. Coexistence of serotonin 3 (5-HT3) and CB1 cannabinoid receptors in interneurons of hippocampus and dentate gyrus.
Morales M; Bäckman C
Hippocampus; 2002; 12(6):756-64. PubMed ID: 12542227
[TBL] [Abstract][Full Text] [Related]
12. Reduced basal activity and increased functional homogeneity in sensorimotor and striatum of a Parkinson's disease rat model: a functional MRI study.
Pelled G; Bergman H; Ben-Hur T; Goelman G
Eur J Neurosci; 2005 Apr; 21(8):2227-32. PubMed ID: 15869519
[TBL] [Abstract][Full Text] [Related]
13. Antiparkinsonian action of a delta opioid agonist in rodent and primate models of Parkinson's disease.
Hille CJ; Fox SH; Maneuf YP; Crossman AR; Brotchie JM
Exp Neurol; 2001 Nov; 172(1):189-98. PubMed ID: 11681851
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of striatal synaptotagmin mRNA isoforms in hemiparkinsonian rats.
Glavan G; Zivin M
Neuroscience; 2005; 135(2):545-54. PubMed ID: 16111820
[TBL] [Abstract][Full Text] [Related]
15. Localization of cannabinoid receptor mRNA in rat brain.
Matsuda LA; Bonner TI; Lolait SJ
J Comp Neurol; 1993 Jan; 327(4):535-50. PubMed ID: 8440779
[TBL] [Abstract][Full Text] [Related]
16. Endocannabinoids and basal ganglia functionality.
Fernández-Ruiz J; Lastres-Becker I; Cabranes A; González S; Ramos JA
Prostaglandins Leukot Essent Fatty Acids; 2002; 66(2-3):257-67. PubMed ID: 12052041
[TBL] [Abstract][Full Text] [Related]
17. Dysfunction of the cortico-basal ganglia-cortical loop in a rat model of early parkinsonism is reversed by metabotropic glutamate receptor 5 antagonism.
Oueslati A; Breysse N; Amalric M; Kerkerian-Le Goff L; Salin P
Eur J Neurosci; 2005 Dec; 22(11):2765-74. PubMed ID: 16324110
[TBL] [Abstract][Full Text] [Related]
18. The activation of cannabinoid receptors during early postnatal development reduces the expression of cell adhesion molecule L1 in the rat brain.
Gómez M; Hernández M; Fernández-Ruiz J
Brain Res; 2007 May; 1145():48-55. PubMed ID: 17320842
[TBL] [Abstract][Full Text] [Related]
19. [Role of endogenous cannabinoids in cerebral reward mechanisms].
Wenger T; Fürst S
Neuropsychopharmacol Hung; 2004 Mar; 6(1):26-9. PubMed ID: 15125311
[TBL] [Abstract][Full Text] [Related]
20. Cortical expression of brain derived neurotrophic factor and type-1 cannabinoid receptor after striatal excitotoxic lesions.
De March Z; Zuccato C; Giampà C; Patassini S; Bari M; Gasperi V; De Ceballos ML; Bernardi G; Maccarrone M; Cattaneo E; Fusco FR
Neuroscience; 2008 Mar; 152(3):734-40. PubMed ID: 18313855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
